FluoXplore

About FluoSphera

FluoSphera has developed a novel, chip-free platform for high-throughput drug discovery that utilizes compartmentalized, color-coded 3D human organ-like microtissues. This system is designed to model the systemic interactions between organs mediated by blood-soluble factors, providing a more physiologically relevant model for predicting drug efficacy, toxicity, and mechanism of action before clinical trials. The company offers integrated discovery products (FluoSelect, FluoScore, FluoXplore) and has established a partnership with Revvity, indicating a platform-as-a-service business model targeting pharmaceutical and biotech clients. Headquartered in Lausanne, Switzerland, with a US presence in Boston, FluoSphera is a private, likely pre-revenue company positioned to address a critical bottleneck in translational research.